The latest deals are between Teva and Indian generics companies Impax Laboratories (Impax) and Zydus Cadilla (Zydus).

Impax announced on 21 June 2016 that it had signed definitive agreements with Teva and affiliates of Allergan to acquire a portfolio of 15 currently marketed generics, along with several other products that are in the pipeline or not yet launched. The portfolio includes a broad range of generics across solid oral, inhalable, injectable and topical dosage forms. The deal will also return to Impax the rights to its pending abbreviated new drug application (ANDA) for the generic equivalent to ADHD (attention deficit/hyperactivity disorder) medication Concerta (methylphenidate).

Zydus announced on 20 June 2016 that it had acquired two ANDAs from Teva through its 100% subsidiary, Zydus Worldwide DMCC. The acquired portfolio comprises an ANDA which is already commercialized and one pipeline ANDA which is a transdermal patch. The estimated market size of the two ANDAs put together is nearly US$200 million.

The deals come as part of a requirement from US authorities in order to approve Teva’s acquisition of Allergan’s generics business [1]. The acquisitions are therefore contingent on the closing of the Teva/Allergan generics transaction and approval by the US Federal Trade Commission of the buyers.

These are just the latest deals coming as a result of the Teva/Allergan merger. Dr Reddy’s Laboratories announced on 11 June 2016 that it would acquire a portfolio of eight ANDAs in the US from Teva [1].

Related article
Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Dr Reddy’s to buy US generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jul 29]. Available from: www.gabionline.net/Generics/News/Dr-Reddy-s-to-buy-US-generics-from-Teva

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.